Insys stock: buy or sell?

INSY stock price: $65,799,000.00 25.00% At close on June 28th, 2019

Updated on:
June 28th, 2019


Insys Therapeutics crossed up the simple moving average line of 200 days today and closed at $65,799,000.00. On June INSY plummed a spooky -11.54%. June session broke a read streak of 4 days in a row.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States.

Should I buy Insys stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

Currently, Insys stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Insys stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At, we collected 2 ratings published for INSY stock in the last 30 days.

Is INSY a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-3-8Royal Bank of CanadaOutperformOutperform
2019-1-22Cantor Fitzgeraldn/aOverweight

Insys stock analysis

Daily outlook

After sliding for 4 sessions, June Insys boosted a super good 25,307,307,592.31%, closing at $65,799,000.00.

After sliding for 4 days, June Insys boosted a super good 25,307,307,592.31%, closing at $65,799,000.00. Since last June when SMA100d and SMA200d crossed up, INSY price gained $65,798,999.74 per share (25,307,307,592.31%). INSY broke out again over $0.74 after a 72.97% correction started on June.

INSY stock chart (daily)

Weekly outlook

Insys shares broke up the SMA line of 200d, closing at $65,799,000.00. By mid June INSY plunged a bloodcurdling -30.77% in just one week.

Since late June when SMA20w and SMA40w crossed up, INSY price gained $65,798,999.74 per share (25,307,307,592.31%).

INSY stock chart (weekly)

Insys stock price history

Insys stock went public on November 2nd, 2017 with a price of $4.791. Since then, INSY stock surged a 1,373,674,221.50%, with a yearly average of 1,373,674,221.50%. If you had invested $1,000 in Insys stock in 2017, it would worth $13,736,742,215.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Insys stock historical price chart

INSY stock reached 52-week highs at $11.65, and all-time highs 2018-01-03 with a price of 14.

Insys stock price target is $7.00

How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we only found 1 price target for Insys Therapeutics stock:
INSY stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-3-8Royal Bank of CanadaLowers Target$9.00$7.00-22.2%
(in average)$9.00$7.00-22.0%

Financials and fundamental analysis

Earnings date and Earnings per Share

On March, Insys reported its latest financial data, posting a phenomenal gain for the Earnings per Share (EPS) ratio. Analyst were expecting $-0.33 per share, but Insys Therapeutics posted $-0.39.
INSY earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual sales report draw a spooky loss of -41.66% to $82.08 M dollars. When comparing 2018 vs 2017, improving that, profit margin (that is, the net income divided by revenues) rose a 9.54% to -151.69%.

INSY annual Sales and Income evolution
2013$99 M-$40 M40.7%-
2014$222 M123.71%$38 M17.1%-5.95%
2015$331 M48.92%$58 M17.7%53.98%
2016$242 M-26.76%$7.59 M3.1%-87.02%
2017$141 M-41.93%$-226.84 M-161.2%-3,088.60%
2018$82 M-41.66%$-124.51 M-151.7%-45.11%

Quarterly financial results

Insys reported $16.36 million in sales for 2018-Q4, a -10.84% less compared to previous quarter. Reported quarter income marked $-46.29 million with a profit margin of -283.02%. Profit margin plummed a -116.80% compared to previous quarter when profit margin was -166.22%. When comparing sales to same quarter last year, Insys Therapeutics sales marked a frightening drop down and collapsed a -48.05%. Looking back to recent quarterly results, Insys posted 4 positive quarters in a row.
INSY quarterly Sales and Income evolution
2017-Q1$36 M-$-6.52 M-18.1%-
2017-Q2$43 M18.41%$-8.18 M-19.2%25.46%
2017-Q3$31 M-27.97%$-166.32 M-542.3%1,933.25%
2017-Q4$31 M2.66%$-47.11 M-149.6%-71.68%
2018-Q1$24 M-24.06%$-20.37 M-85.2%-56.76%
2018-Q2$23 M-1.86%$-27.35 M-116.6%34.27%
2018-Q3$18 M-21.82%$-30.49 M-166.2%11.50%
2018-Q4$16 M-10.84%$-46.29 M-283.0%51.81%

Insys ownership

When you are planning to buy shares of a stock, it's worth to review its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Insys, of all outstanding shares are owned by its staff.

The following table compares ownership indicators for other stocks related to Insys Therapeutics:

Market cap$0.0 M
Total shares0.0 M
Float shares0.0 M
  - Institutional holdings (%)0.0%
  - Insider holdings (%)0.0%
Shares in short selling0.0%

Insys summary

Friday, June 28th, 2019
Day range$0.25 - $0.38
Previous close$0.26
Session gain25,307,307,592.31%
Average true range$0.31
50d mov avg$1,315,980.00
100d mov avg$657,994.00
200d mov avg$329,000.00
Daily patternlb01c
Weekly pattern lb06c

Insys performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We picked as the bechmarking frame for Insys Therapeutics stock.
INSYInsys Therapeutic...1424220000.00%1896220000.00%908826000.00%

Insys competitors

Unfortunately, we could not find any public company that could be defined as Insys Therapeutics competitor. This doesn't mean Insys Therapeutics does not have any competitor in the market, it's just we could not detected it.